Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Total Current Liabilities (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Total Current Liabilities data on record, last reported at $9.9 million in Q1 2026.

  • On a quarterly basis, Total Current Liabilities rose 21.78% to $9.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $9.9 million, a 21.78% increase, with the full-year FY2025 number at $13.0 million, up 18.15% from a year prior.
  • Total Current Liabilities reached $9.9 million in Q1 2026 per FULC's latest filing, down from $13.0 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for FULC hit a ceiling of $22.1 million in Q2 2022 and a floor of $8.1 million in Q1 2025.
  • A 5-year average of $13.5 million and a median of $13.7 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: crashed 33.08% in 2023, then increased 21.78% in 2026.
  • Tracing FULC's Total Current Liabilities over 5 years: stood at $16.7 million in 2022, then dropped by 18.24% to $13.7 million in 2023, then fell by 19.24% to $11.0 million in 2024, then increased by 18.15% to $13.0 million in 2025, then decreased by 24.4% to $9.9 million in 2026.
  • Business Quant data shows Total Current Liabilities for FULC at $9.9 million in Q1 2026, $13.0 million in Q4 2025, and $11.6 million in Q3 2025.